Title: Insulin Infusion: A Therapeutic Approach to Managing Severe Hypertriglyceridemia
Presenter: Marsa Esmaeili-Koosej, PharmD, PGY1 HSPAL Resident
Project mentor: Lara Groetzinger, PharmD, BCCCP
Presentation Date: 07/24/2024

Learning Objectives:

1. Define the biochemical mechanisms underlying insulin infusion therapy in reducing triglyceride levels in severe hypertriglyceridemia.
2. Explain the clinical efficacy of insulin infusion therapy for severe hypertriglyceridemia by examining relevant research findings and outcomes.
3. Discuss practical applications and clinical considerations for implementing insulin infusion therapy in patients with severe hypertriglyceridemia.

Abstract:

Hypertriglyceridemia (HTG) is a significant risk factor for both atherosclerotic cardiovascular disease and acute pancreatitis (AP). Severe HTG, characterized by triglyceride (TG) levels above 500 mg/dL, is responsible for approximately 20% of AP cases. Currently, there is no standardized treatment protocol for managing severe HTG.[1]

Potential interventions for HTG include plasmapheresis and intravenous insulin infusions. Plasmapheresis effectively lowers TG levels but is not recommended as a first-line treatment due to its high costs and potential complications. [2] Other options, such as fibrates, omega-3 fatty acids, niacin, and HMG-CoA reductase inhibitors, have limited benefits due to their delayed onset of effect and are most effectively used as adjunct therapies.[3,4]

Intravenous insulin infusions, on the other hand, reduce TG levels by enhancing the metabolism of chylomicrons and very low-density lipoproteins (VLDLs). [5] Despite numerous studies investigating intravenous insulin infusions for severe HTG, a consistent administration protocol has not been established, and the literature does not uniformly support their benefits and safety.

This presentation aims to assess the safety and effectiveness of intravenous insulin infusions for the management of severe HTG. Establishing a standardized protocol could ensure the safe and effective reduction of TG levels in patients with severe HTG, providing valuable insights for optimizing treatment strategies and potentially improving patient outcomes.

References:

1. Yang, Allison L, and Julia McNabb-Baltar. “Hypertriglyceridemia and acute pancreatitis.” *Pancreatology* : official journal of the International Association of Pancreatology (IAP) ... [et al.] vol. 20,5 (2020): 795-800. doi:10.1016/j.pan.2020.06.005

2. Xiao, Amy Y et al. “Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies.” *The lancet. Gastroenterology & hepatology* vol. 1,1 (2016): 45-55. doi:10.1016/S2468-1253(16)30004-8

3. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of Hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2012;97(9):2969-2989.

4. Rawla, Prashanth et al. “Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies.” *Clinical journal of gastroenterology* vol. 11,6 (2018): 441-448. doi:10.1007/s12328-018-0881-1

5. Hoff, Abigail, and Kara Piechowski. “Treatment of Hypertriglyceridemia with Aggressive Continuous Intravenous Insulin.” *Journal of pharmacy & pharmaceutical sciences* : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques vol. 24 (2021): 336-342. doi:10.18433/jpps32116

Audience Response Questions:

Knowledge Check 1: Which of the following statements regarding insulin infusion for hypertriglyceridemia is correct?

a) Insulin primarily acts by directly reducing triglyceride levels in the bloodstream.
b) Insulin infusion is contraindicated in patients with hypertriglyceridemia due to the risk of hypoglycemia.
c) Insulin infusion stimulates lipoprotein lipase activity, facilitating triglyceride clearance from circulation.
d) Insulin infusion for hypertriglyceridemia is typically administered orally.

Knowledge Check 2: Which of the following monitoring parameters is essential during intravenous insulin therapy for the management of hypertriglyceridemia-induced acute pancreatitis?

a) Serum TG levels every 4 hours
b) Continuous electrocardiogram (ECG) monitoring
c) Hourly blood glucose levels
d) Daily liver function tests

Knowledge Check 3: In the management of hypertriglyceridemia, when is insulin infusion typically indicated?

a) When serum TG levels exceed 1000 mg/dL regardless of clinical symptoms
b) In cases of severe hypertriglyceridemia (>1000 mg/dL or with evidence of acute pancreatitis or when TG levels are rapidly rising despite conventional therapy
c) Only in patients with a history of insulin resistance
d) When other lipid-lowering agents fail to reduce TG levels below 500 mg/dL